biote Corp. (BTMD)
5.67
0.13 (2.35%)
At close: Jan 14, 2025, 3:59 PM
5.79
2.12%
Pre-market Jan 15, 2025, 07:26 AM EST
undefined% (undefined)
| Bid | 5.79 |
| Market Cap | 308.09M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.3 |
| PE Ratio (ttm) | 18.9 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.85 |
| Volume | 61,880 |
| Avg. Volume (20D) | 134,627 |
| Open | 5.65 |
| Previous Close | 5.54 |
| Day's Range | 5.50 - 5.71 |
| 52-Week Range | 3.65 - 8.44 |
| Beta | undefined |
About BTMD
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was fou...
Industry Medical - Care Facilities
Sector Healthcare
IPO Date Apr 28, 2021
Employees 194
Stock Exchange NASDAQ
Ticker Symbol BTMD
Website https://biote.com
Analyst Forecast
According to 5 analyst ratings, the average rating for BTMD stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 58.73% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
biote Corp. is scheduled to release its earnings on Mar 11, 2025,
during market hours.
Analysts project revenue of $51.29M, reflecting a 12.22% YoY growth and earnings per share of 0.17, making a -5.56% decrease YoY.
Analysts project revenue of $51.29M, reflecting a 12.22% YoY growth and earnings per share of 0.17, making a -5.56% decrease YoY.
5 months ago ·
Source
-18.91%
Biote shares are trading lower after the company r...
Unlock content with
Pro Subscription
8 months ago ·
Source
-1.91%
Biote shares are trading lower after J Capital issued a short report on the stock.
